Российское сообщество больных Гепатитом С

3.4.1 HCV Antibody

Using their Trimera mouse system to produce human antibodies to the hepatitis C virus, XTL Biopharmaceuticals claims that these antibodies are more potent and specific and more effective than previously generated antibodies. (The Trimera mouse has been genetically altered to carry human tissues for in vivo [in a living organism] experiments.) These antibodies are now being investigated, and the product is called Nabi-Civacir. Tested in chimpanzees with encouraging results, Nabi-Civacir, (a.k.a. H-CIG) is a human antibody to hepatitis C, derived from screened donors. These antibodies neutralize the hepatitis C virus and it is hoped they might prevent HCV infection or subsequent re-infection. The product is now in Phase II trials in transplant patients.

In several animal studies, sustained levels of Civacir seemed to reduce viral loads, and possibly eliminate HCV altogether. More studies are required ( www.nabi.com/prodev/corpa5.htm#civacir).

XTL has another product, HCV-AB68, a monoclonal antibody. Phase 1A trials involving one application in a few Hep C patients have been completed, showing it to be safe, well-tolerated and effective. Dose-escalating trials are underway (http://www.hivandhepatitis.com/hep_c/news/011003a.html#hcv  



Яндекс цитирования

Сайт управляется системой uCoz